What Residency Won’t Tell You About Off-Label GLP-1 Prescribing Mistakes

Why do GLP-1 prescribing mistakes happen most often in the hands of people who feel completely sure they know what they’re doing?

Because confidence is a terrible safety system.

Off-label GLP-1 prescribing means you’re using a medication outside its FDA-approved indication, dosing framework, or clinical context. Sometimes that’s thoughtful medicine. Sometimes it’s just hype in a white coat. And right now, enthusiasm is outrunning discipline. I’ve seen clinicians act like writing a GLP-1 is the modern version of ordering a multivitamin—quick visit, vague goal, minimal counseling, weak follow-up. That’s how patients get hurt.

The usual failures are painfully predictable:

• The wrong patient gets selected.
• The titration goes too fast.
• Side effects are brushed off until they’re not minor anymore.
• Documentation is so sloppy it can’t protect the patient or the prescriber.

This isn’t about being anti-GLP-1. These drugs can be excellent tools. But tools cut both ways. Off-label use demands more rigor, not less. If you prescribe by demand, by trend, or by half-remembered dosing logic, you are setting up the exact mess residency rarely prepares you to clean up.

Mistake #1: Prescribing Before Confirming the Right Patient

The first mistake happens before the first pen is uncapped.

Do not assume that every patient asking for weight loss help, “metabolic optimization,” or appetite control is a reasonable GLP-1 candidate. Patients are persuasive. Social media is worse. Neither should drive your prescribing.

Here’s where people get reckless: they hear “motivated patient,” see an elevated BMI, and skip the deeper screening. Bad move.

Red flags you should not blow past

• Personal or family history of medullary thyroid carcinoma
• History of MEN2
• Prior pancreatitis
• Severe GI disease or significant baseline gastroparesis-type symptoms
• Pregnancy or intent to become pregnant
• Active or poorly controlled eating disorder
• Patient cannot or will not do reliable follow-up
• Chaotic medication use, low health literacy, or inability to understand titration instructions

Any one of these should slow you down. Sometimes stop you cold.

Baseline assessment you actually need

Before prescribing, confirm:

1. What is the indication?
   BMI alone is not a complete thought. Are you treating obesity, diabetes-related risk, cardiometabolic disease, or something else?

2. What is the diabetes status?
   Prediabetes, type 2 diabetes, no diabetes? This changes the risk-benefit discussion and the interaction profile.

3. What is the cardiovascular risk picture?
   Don’t ignore hypertension, ASCVD, sleep apnea, fatty liver disease, or kidney issues.

4. What other medications are onboard?
   Especially insulin, sulfonylureas, drugs with narrow timing needs, and anything that GI slowing could complicate.

5. What does success actually mean?
   If the patient expects dramatic weight loss in four weeks with zero nausea and no lifestyle work, your problem has already started.

I’ve seen the classic bad consult: “Patient requests GLP-1 for weight loss, risks discussed.” That note tells me almost nothing. It also tells me the prescriber got lazy.

Mistake #2: Getting the Dose Escalation Wrong

This is the most common operational mistake. And it’s dumb because it’s preventable.

Clinicians rush the titration. Patients push to increase early. Pharmacies substitute confusion for clarity. Then everyone acts surprised when the patient is vomiting for three days and can’t keep fluids down.

The trap: moving too fast

Rapid dose escalation is one of the fastest ways to create:

• Nausea
• Vomiting
• Dehydration
• Missed work
• ED visits
• Early discontinuation of a drug that might have worked if you’d just been patient

Don’t prescribe like you’re trying to win a race. The GI tract does not care about your schedule.

The other trap: product confusion

This is where things get ugly fast:

• Wrong GLP-1 product
• Wrong pen strength
• Wrong concentration
• Wrong units
• Confusion between branded and compounded formulations
• Patient instructed in “mL” when they’re thinking in “mg”
• Pharmacy label that doesn’t match what you intended

I’ve seen charts where the medication name was documented vaguely, the concentration wasn’t written, and the follow-up message said “increase as tolerated.” That is not a titration plan. That is an invitation to error.

What your prescription and note must spell out

Document the exact:

• Drug name
• Formulation
• Concentration
• Starting dose
• Escalation schedule
• Maximum planned dose
• Criteria to hold
• Criteria to reduce
• What to do if a dose is missed
• What side effects require a call

If the product is compounded, be even more explicit. More on that in a minute.

A vague order is not efficient. It’s reckless. Especially with medications patients are often intensely motivated to keep taking even when their body is telling them to stop.

Mistake #3: Ignoring Monitoring, Side Effects, and Drug Interactions

A GLP-1 prescription is not a one-time event. Follow-up is part of the drug. If you can’t monitor, don’t prescribe.

I get especially worried when the note sounds clean and the plan is empty: “Start medication, follow up PRN.” No. That’s how side effects simmer until they become complications.

Common effects are common. Don’t pretend otherwise.

Most prescribers know nausea can happen. Fewer act like it matters. But patients remember exactly how you frame it. If you minimize too much, they either stop silently or push through symptoms they should’ve reported earlier.

Expected issues may include:

• Nausea
• Early satiety
• Constipation
• Vomiting
• Reflux or dyspepsia
• Reduced oral intake

The question isn’t whether symptoms exist. The question is whether they’re still tolerable and safe.

Red flags that should trigger reassessment now

• Persistent vomiting
• Severe abdominal pain
• Inability to maintain hydration
• Dizziness or orthostasis
• Gallbladder-type symptoms
• Worsening reflux that limits eating or sleeping
• Evidence of medication intolerance that is escalating, not settling

Patients often underreport until things are bad. Ask directly. “Are you keeping fluids down?” works better than “Any side effects?”

Interaction traps people miss

1. Insulin or sulfonylureas
   If you add a GLP-1 without thinking through background hypoglycemia risk, you’re asking for trouble. Dose adjustments may be needed. Don’t discover this after the patient gets shaky, confused, or worse.

2. Delayed gastric emptying
   This can affect how other medications are tolerated or absorbed. Timing-sensitive drugs deserve a second look. Don’t just click renew on the whole med list and call it coordination.

3. Escalating intolerance that gets mislabeled as “normal”
   Some discomfort can happen. Persistent inability to eat, drink, or function is not “normal.” That’s where sloppy reassurance hurts people.

My rule is simple: if a patient can’t clearly tell me the plan for side effects, I haven’t counseled well enough. And if I can’t tell from the chart when I’m checking back in, I haven’t prescribed safely enough.

Mistake #4: Weak Documentation, Consent, and Compounding Oversight

This is the mistake clinicians dismiss—right up until it burns them.

Off-label prescribing is not unethical by default. But off-label prescribing without clear rationale, informed consent, and exact documentation is bad medicine. Full stop.

What weak documentation causes

• Pharmacy confusion
• Prior authorization failure
• Broken continuity when another clinician inherits the patient
• Unclear dosing after adverse effects
• Medicolegal vulnerability if the outcome turns ugly

I’ve read notes that said, “Patient aware of risks.” Which risks? What alternatives? What formulation? What follow-up plan? That sentence protects nobody.

What you should document every time

• Why this medication is being used off-label
• Why it is appropriate for this specific patient
• Contraindications reviewed and relevant negatives
• Risks, benefits, and alternatives discussed
• Patient questions answered
• Informed consent documented
• Exact product details and titration instructions
• Monitoring plan and follow-up interval

Compounded GLP-1s: where good intentions become preventable errors

Compounded products are not a casual workaround. This is one of the biggest modern traps.

Before endorsing or prescribing around a compounded formulation, verify:

• Source
• Concentration
• Exact active ingredient/formulation
• Dosing instructions
• Patient understanding
• Regulatory limitations in your setting

If you cannot verify what’s in the vial, how it should be measured, and how it maps to your intended dose, do not guess. Guessing with a compounded injectable is not innovation. It’s negligence dressed up as access.

Closing: The Mistakes That Matter Most

The four mistakes are the same every time:

1. Wrong patient
2. Wrong dose or titration
3. Weak monitoring
4. Weak documentation

That’s the whole story. Not glamorous. Not trendy. Just the truth.

The protective mindset matters more than the prescription itself. Slow down. Verify the indication. Screen for red flags. Write the exact plan. Follow the patient after you start. And don’t let hype bully you into pretending a high-stakes medication is simple.

GLP-1 drugs can help a lot of people. I’m not arguing otherwise. I’m arguing against lazy prescribing, vague counseling, and “everybody’s doing it” medicine. Off-label use deserves the same rigor you’d bring to any decision with real downside. Maybe more.

Because the mistake that harms a patient usually doesn’t look dramatic at the start. It looks efficient. It looks routine. It looks like a shortcut.

Don’t take it.